References of "Osteoporosis International"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailIdentification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting.
Kanis, J.A.; Cooper, C.; Rizzoli, R. et al

in Osteoporosis International (2017), 28(7), 2023-2034

Summary: Osteoporosis represents a significant and increasing healthcare burden in Europe, but most patients at increased risk of fracture do not receive medication, resulting in a large treatment gap ... [more ▼]

Summary: Osteoporosis represents a significant and increasing healthcare burden in Europe, but most patients at increased risk of fracture do not receive medication, resulting in a large treatment gap. Identification of patients who are at particularly high risk will help clinicians target appropriate treatment more precisely and cost-effectively, and should be the focus of future research. Introduction: The purpose of the study was to review data on the identification and treatment of patients with osteoporosis at increased risk of fracture. Methods: Aworking group convened by the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis met to review current data on the epidemiology and burden of osteoporosis and the patterns of medical management throughout Europe. [less ▲]

Detailed reference viewed: 17 (3 ULiège)
Full Text
Peer Reviewed
See detailOsteoarthritis increases the risk of cardiovascular disease: data from the osteoarthritis initiative.
Veronese, N.; Smith, T; Reginster, Jean-Yves ULiege et al

in Osteoporosis International (2017, March), 28 Suppl 1

Detailed reference viewed: 15 (2 ULiège)
Full Text
Peer Reviewed
See detailPublic Health impact and economic evaluation of vitamin D-fortified dairy products for fracture prevention in France.
HILIGSMANN, M.; BURLET, N.; FARDELLONE, P. et al

in Osteoporosis International (2017), 28(3), 833-840

Summary: The recommended intake of vitamin D-fortified dairy products can substantially decrease the burden of osteoporotic fractures and seems an economically beneficial strategy in the general French ... [more ▼]

Summary: The recommended intake of vitamin D-fortified dairy products can substantially decrease the burden of osteoporotic fractures and seems an economically beneficial strategy in the general French population aged over 60 years. Introduction: This study aims to assess the public health and economic impact of vitamin D-fortified dairy products in the general French population aged over 60 years. Methods: We estimated the lifetime health impacts expressed in number of fractures prevented, life years gained, and quality-adjusted life years (QALY) gained of the recommended intake of dairy products in the general French population over 60 years for 1 year (2015). A validated microsimulation model was used to simulate three age cohorts for both women and men (60–69, 70–79, and >80 years). The incremental cost per QALY gained of vitamin D-fortified dairy products compared to the absence of appropriate intake was estimated in different populations, assuming the cost of two dairy products per day in base case. Results: The total lifetime number of fractures decreased by 64,932 for the recommended intake of dairy products in the general population over 60 years, of which 46,472 and 18,460 occurred in women and men, respectively. In particular, 15,087 and 4413 hip fractures could be prevented in women and men. Vitamin D-fortified dairy products also resulted in 32,569 QALYs and 29,169 life years gained. The cost per QALY gained of appropriate dairy intake was estimated at €58,244 and fall below a threshold of €30,000 per QALY gained in women over 70 years and in men over 80 years. Conclusion: Vitamin D-fortified dairy products have the potential to substantially reduce the burden of osteoporotic fractures in France and seem an economically beneficial strategy, especially in the general population aged above 70 years. [less ▲]

Detailed reference viewed: 5 (2 ULiège)
Full Text
Peer Reviewed
See detailInternational Osteoporosis Foundation and European Calcified Tissue Society working group. Recommendations for the screening of the adherence to oral bisphosphonates.
DIEZ-PEREZ, A; NAYLOR, K.E.; ABRAHAMSEN, B et al

in Osteoporosis International (2017), 28(3), 767-774

Summary: Adherence to oral bisphosphonates is low. A screening strategy is proposed based on the response of biochemical markers of bone turnover after 3 months of therapy. If no change is observed, the ... [more ▼]

Summary: Adherence to oral bisphosphonates is low. A screening strategy is proposed based on the response of biochemical markers of bone turnover after 3 months of therapy. If no change is observed, the clinician should reassess the adherence to the treatment and also other potential issues with the drug. Introduction: Low adherence to oral bisphosphonates is a common problem that jeopardizes the efficacy of treatment of osteoporosis. No clear screening strategy for the assessment of compliance is widely accepted in these patients. Methods: The International Osteoporosis Foundation and the European Calcified Tissue Society have convened a working group to propose a screening strategy to detect a lack of adherence to these drugs. The question to answer was whether the bone turnover markers (BTMs) PINP and CTX can be used to identify low adherence in patients with postmenopausal osteoporosis initiating oral bisphosphonates for osteoporosis. The findings of the TRIO study specifically address this question and were used as the basis for testing the hypothesis. Results: Based on the findings of the TRIO study, specifically addressing this question, the working group recommends measuring PINP and CTX at baseline and 3 months after starting therapy to check for a decrease above the least significant change (decrease of more than 38% for PINP and 56% for CTX). Detection rate for the measurement of PINP is 84%, for CTX 87% and, if variation in at least one is considered when measuring both, the level of detection is 94.5%. Conclusions: If a significant decrease is observed, the treatment can continue, but if no decrease occurs, the clinician should reassess to identify problems with the treatment, mainly low adherence. [less ▲]

Detailed reference viewed: 15 (4 ULiège)
Full Text
Peer Reviewed
See detailDaily management of knee osteoarthritis: from the ESCEO algorithm to the CONCEPT study.
Reginster, Jean-Yves ULiege

in Osteoporosis International (2017, March), 28 Suppl 1

Detailed reference viewed: 38 (2 ULiège)
Full Text
Peer Reviewed
See detailBiomarkers of osteoarthritis : practical considerations.
CAVALIER, Etienne ULiege; Reginster, Jean-Yves ULiege

in Osteoporosis International (2017, March), 28 Suppl 1

Detailed reference viewed: 34 (2 ULiège)
Full Text
Peer Reviewed
See detailPrevalence of sarcopenia accoring to 10 different operational definitions of the frailty.
Buckinx, Fanny ULiege; Reginster, Jean-Yves ULiege; Beaudart, Charlotte ULiege et al

in Osteoporosis International (2017, March), 28 Suppl 1

Detailed reference viewed: 25 (4 ULiège)
Full Text
Peer Reviewed
See detailProfile of osteoarthritic patients undergoing total hip and knee arthroplasty.
Neuprez, Audrey ULiege; KURTH, William ULiege; GILLET, Philippe ULiege et al

in Osteoporosis International (2017, March), 28 Suppl 1

Detailed reference viewed: 27 (4 ULiège)
Full Text
Peer Reviewed
See detailThe SarcoPhAge study: evolution of sarcopenic subjects after 2 years of follow-up.
Beaudart, Charlotte ULiege; Locquet, Médéa ULiege; Reginster, Jean-Yves ULiege et al

in Osteoporosis International (2017, March), 28 Suppl 1

Detailed reference viewed: 30 (2 ULiège)
Full Text
Peer Reviewed
See detailBone quality assessment among sarcopenic and non sarcopenic elderly subjects from the SarcoPhAge Study.
Locquet, Médéa ULiege; Beaudart, Charlotte ULiege; Delandsheere, Laura ULiege et al

in Osteoporosis International (2017, March), 28 Suppl 1

Detailed reference viewed: 26 (2 ULiège)
Full Text
Peer Reviewed
See detailThe relationship between knee osteoarthritis and incident hypertension: a representative longitudinal study.
Veronese, N.; Stubbs, B.; Smith, T. et al

in Osteoporosis International (2017, March), 28 Suppl 1

Detailed reference viewed: 26 (2 ULiège)
Full Text
Peer Reviewed
See detailLow bone mineral density and fractures are associated with incident cardiovascular disease: a systematic review and meta-analysis.
Veronese, N.; Stubbs, B.; Crepaldi, G. et al

in Osteoporosis International (2017, March), 28 Suppl 1

Detailed reference viewed: 31 (2 ULiège)
Full Text
Peer Reviewed
See detailThe risk of subsequent osteoporotic fractures is decreased in patients experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies.
Kendler, D.L.; Chines, A.; Brandi, M.L. et al

in Osteoporosis International (2017, March), 28 Suppl 1

Detailed reference viewed: 28 (3 ULiège)
Full Text
Peer Reviewed
See detailSubjective sleep quality in sarcopenic vs non-sarcopenic older adults from the sarcophage cohort.
Locquet, Médéa ULiege; Beaudart, Charlotte ULiege; Delandsheere, Laura ULiege et al

in Osteoporosis International (2017, March), 28 Suppl 1

Detailed reference viewed: 15 (2 ULiège)
Full Text
Peer Reviewed
See detailSarcopenia in nursing home residents: the senior cohort.
Buckinx, Fanny ULiege; Reginster, Jean-Yves ULiege; Beaudart, Charlotte ULiege et al

in Osteoporosis International (2017, March), 28 Suppl 1

Detailed reference viewed: 26 (5 ULiège)
Full Text
Peer Reviewed
See detailPublic health and economic impact of vitamin D-fortified dairy products for fracture prevention in France.
Hiligsmann, M.; Burlet, N.; Fardellone, P. et al

in Osteoporosis International (2017, March), 28 Suppl 1

Detailed reference viewed: 25 (2 ULiège)